Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $50.5 million.

  • Vanda Pharmaceuticals' Receivables - Net rose 1821.63% to $50.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.5 million, marking a year-over-year increase of 1821.63%. This contributed to the annual value of $47.1 million for FY2024, which is 3790.37% up from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Receivables - Net stood at $50.5 million, which was up 1821.63% from $45.0 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Receivables - Net registered a high of $50.5 million during Q3 2025, and its lowest value of $24.5 million during Q1 2023.
  • Moreover, its 5-year median value for Receivables - Net was $34.2 million (2023), whereas its average is $36.6 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 5085.21% in 2021, then crashed by 2926.55% in 2022.
  • Over the past 5 years, Vanda Pharmaceuticals' Receivables - Net (Quarter) stood at $32.5 million in 2021, then rose by 3.22% to $33.5 million in 2022, then grew by 1.92% to $34.2 million in 2023, then soared by 37.9% to $47.1 million in 2024, then increased by 7.3% to $50.5 million in 2025.
  • Its last three reported values are $50.5 million in Q3 2025, $45.0 million for Q2 2025, and $44.6 million during Q1 2025.